Cowen Raises Sage Value On New Phase 2 Trial Success

0 Comments 1 view(s)

SAGE Therapeutics Inc (NASDAQ: SAGE) released Thursday positive top-line data from its Phase 2 study of SAGE-217 in major depressive disorder (MDD).

Latest Ratings for SAGE

Date Firm Action From To
Nov 2017 BMO Capital Maintains Outperform
Nov 2017 Bank of America Maintains Buy
Nov 2017 Canaccord Genuity Maintains Buy

View More Analyst Ratings for SAGE

View the Latest Analyst Ratings

read more